LONDON, Jan. 30, 2020 /PRNewswire/ -- Erba Mannheim strengthens its portfolio of powerful and affordable solutions with a burst of new launches and a preview of their next generation NEXUS total lab automation system.

NEXUS total lab automation will offer powerful, modular solutions using advanced imaging and artificial intelligence. The NEXUS IA immunoassay analyzer uses unique magnetic CLIA bead technology and extensive panels to deliver a reliable and affordable solution, whilst the  Nexus H Infinity Hematology analyzer uses computer vision to actually 'see' the sample and provides advanced diagnostics by counting, staining, imaging and analyzing 1000's of cells in less than a minute.

New Launches

  • Clinical Chemistry: New EC 90 electrolyte analyser with next generation thick film, maintenance-free electrodes in all-in-one sensor cartridge.
  • Diabetes: New HB715 automated desktop analyzer measuring glycated hemoglobin (HbA1c, HbA1ab, HbA1c, HbF, HbA0, HbA2/E/D, HbS, HbC) and designed for ease of use and low-cost operation.
  • Immunoassay: New ELAN 30s analyzer & New Rapid Tests– fully automated compact benchtop ELISA microstrip processor performing 6 different tests simultaneously, and Rapid Malaria and Dengue Tests with unique Dual Colour Detection system.
  • Hematology: New ESL 30 – fully automated ESR testing solution that improves result quality, laboratory safety and efficiency in mid-sized labs at an affordable price.
  • LIMS Software: a comprehensive middleware solution for integration of results from Erba and non-Erba instruments.

Alongside new products, updated versions of signature XL 200 and XL 640+ clinical chemistry analysers will be presented.

"At MEDLAB ME, we continue to demonstrate our commitment to becoming a leading player in the IVD market. With NEXUS we offer a unique entry level system for Total Lab Automation, enabling labs to scale their business with higher automation. Also, by significantly strengthening our product portfolio for small and medium sized labs and growing our global customer base, we are well placed to achieve our ambition."  Romain Fournials, CCO.

Visit Erba Mannheim on booth Z4.B10, Hall 4 at MEDLAB ME 3-6 Feb 2020.

About Erba Mannheim

Erba Mannheim is a global company focused on delivering innovative, affordable and sustainable healthcare solutions. Operating and providing clinical diagnostic products in over 100 countries, Erba Mannheim utilizes a combination of cutting-edge European R&D with efficient low-cost manufacturing to produce innovative technologies, accessible to labs in all resource settings.

Contact: Arlene Hooper, Global Marketing Communications Manager, +44(0)7494208556, a.hooper@erbamannheim.com

SOURCE Erba Mannheim

Web Site: http://www.erbamannheim.com/

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.